Home/Pipeline/AmoyDx BRCA1/2 Mutation Detection Kit

AmoyDx BRCA1/2 Mutation Detection Kit

Prostate Cancer / Ovarian Cancer

CommercialApproved as CDx for AKEEGA (niraparib/abiraterone) in China

Key Facts

Indication
Prostate Cancer / Ovarian Cancer
Phase
Commercial
Status
Approved as CDx for AKEEGA (niraparib/abiraterone) in China
Company

About Amoy Diagnostics

A precision oncology diagnostics company developing PCR and NGS-based companion diagnostic kits for cancer, with a focus on accessibility and global partnerships.

View full company profile

Therapeutic Areas